SAFETY ASSESSMENT OF ARYLACETAMIDE DERIVATIVE GR 89,696 WITH ANALGESIC ACTIVITY

Cover Page

Cite item

Full Text

Abstract

The analgesic activity and side effects of arylacetamide derivative GR 89,696 have been studied. It has been shown that the occurrence of analgesic effect is accompanied by a change in the ratio between pain and alternative patterns of behavior, while the decrease in the severity of normal behavior is observed only after the introduction of the sample at a maximum analgesic dose of 2000 |ig/kg. The consistent developments of fading, adynamia, weakening of the flip reflex, a significant increase in diuresis are the side effects of intramuscular administration of the sample in the dose range of 1-100 |ig/kg. Negative influence of the sample on respiratory and cardiovascular functions of animals has not been revealed. Therapeutic index (more than 2900) and safety factor (less than 0.02) calculated on the basis of the obtained data allow to consider GR 89,696 as a potential anesthetic, however, to establish the possibility of its practical use a more detailed study of the side effects of the compound is necessary.

About the authors

A. F. Bykova

Scientific Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Author for correspondence.
Email: anna-kurpyakova@rambler.ru

Bykova Anna Fedorovna

195043, Saint Petersburg

Russian Federation

S. E. Galan

Scientific Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: sergey-x-70@mail.ru

Galan Sergej Evgen’evich

195043, Saint Petersburg

Russian Federation

V. Yu. Malyagin

Scientific Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: fake@neicon.ru

Maljagin Vadim Jur’evich

195043, Saint Petersburg

Russian Federation

S. N. Subbotina

Scientific Research Testing Institute of Military Medicine, Ministry of Defense of the Russian Federation

Email: ssubbotina@inbox.ru

Subbotina Svetlana Nikolaevna

195043, Saint Petersburg Russian Federation

References

  1. Guzevatykh L.S. Search for new means of pharmacological regulation of pain sensitivity among fragments of atypical opioid peptides: autoref. dis... Doc. Biol. Sciences, M.; 2009 (in Russian).
  2. Fields, H. L. The doctor's dilemma: opiate analgesics and chronic pain. Neuron. 2011; 69 (4): 591-594.
  3. Ahlbeck K. Opioids: a two-faced Janus. Curr. Med. Res. Opin. 2011; 27 (2): 439-448.
  4. Kubanin A.N., PchelintsevE.E. Opioid analgesics: ways to improve the treatment of pain. Russian Medical Journal 2007; 5: 417-425 (in Russian).
  5. Ignatov Yu.D., ZaitsevA.A. Modern aspects of pain therapy: opiates. Good clinical practice. 2001; 2: 2-13 (in Russian).
  6. Kivell B., Prisinzano T.E. Kappa opioids and the modulation of pain. Psychopharmacology. 2010; 210 (2): 109-119.
  7. CollettB.J. Opioid tolerance: the clinical perspective. Br. J. Anaesth. 1998; 81 (1): 58-68.
  8. Ballantyne J.C., Mao J. Opioid therapy for chronic pain. N. Engl. J. Med. 2003; 349 (20): 1943-1953.
  9. Lemos J.C., Chavkin C. Kappa opioid receptor function. In: Pasternak G., ed. The opiate receptors. 2nd ed. New York: Humana; 2011: 226-305.
  10. Vanderah T. W. Delta and kappa opioid receptors as suitable drug targets for pain. Clin. J. Pain. 2010; 26 (Supplement. 10): 10-15.
  11. Carlezon W.A. Jr., Begin C., Knoll A.T., Cohen B. M. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol. Ther. 2009; 123 (3): 334-343.
  12. Raehal K.M., Bohn L.M. Mu opioid receptor regulation and opiate responsiveness. AAPS J. 2005; 7 (3): 587-591.
  13. Yekkirala A.S. Opioid receptors in analgesic drug design - the past, present and future. J. of Postdoctoral Research. 2013; 1 (4): 9-23.
  14. Rusovici D.E., Negus S.S., Mello N.K., Bidlack J.M. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur. J. Pharmacol. 2004; 485 (1): 119-125.
  15. Nagase H., Fujii H. Opioids in preclinical and clinical trials. Top. Curr. Chem. 2011; 299: 29-62.
  16. Aldrich J.V. Narcotic Analytics. Am. J. Pharm. Educ. 1993; 57: 153-161.
  17. Piercey M.F., Einspahr F.J. Spinal analgesic actions of kappa receptor agonists, U 50488H and spiradoline (U-62066). J. Pharmacol. Exp. Ther. 1989; 251: 267-271.
  18. Gharagozlou P., Hashemi E., DeLorey T.M., Clark D.G., Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006; 6:3.
  19. Kumar V., Marella, M.A., Cortes-Burgos L., Chang A.C., Cassel, J.A., Daubert, J.D. et al. Arylacetamides as peripherally restricted kappa opioid receptor agonists. Bioorg. Med. Chem. Lett. 2000; 10 (22): 2567-2570.
  20. Vonvoigtlander P.F., Lahti R.A., Ludens J.H. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 1983; 224 (1): 7-12.
  21. Pande A.C., Pyke R.E., Greiner M., Cooper S.A., Benjamin R., Pierce M.W. Analytical efficiency of the kappa-receptor agonist, enadoline, in dental surgery pain clinic. Neuropharmacol., 19 (1), 92-97 (1996).
  22. Kumor K.M., Haertzen C.A., Johnson R.E., Kocher T., Jasinski D. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J. Pharmacol. Exp. Ther. 1986; 238 (3): 960-968.
  23. Wadenberg M.L. A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist. CNS Dr. Rev. 2003; 9 (2): 187-201.
  24. Reece P.A., Sedman A.J., Rose S., Wright D.S., Dawkins R., Rajagopalan R. Diuretic effects, pharmaceuticals, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J. Clin. Pharmacol. 1994; 34 (11): 1126-1132.
  25. Mironov A. N., ed. Guidelines for preclinical studies of drugs. Part 1. M.: Grif and K, 2012 (in Russian).
  26. Buresh J., Buresova O., Houston J. P. Techniques and basic experiments for study of brain and behavior. M.: Higher school; 1991 (in Russian).
  27. Shiotsuki H., Yoshim K., Shimo Y. A rotarod test for evaluation of motor skill learning. J. Neurosci. Methods. 2010; 189 (2): 180-185.
  28. Junkerov V.I., Grigoriev S.I. Mathematical and statistical processing of medical research data. SPb.: MMA, 2005 (in Russian).
  29. Belenky M.L. Elements of quantitative assessment of pharmacological effect. L.: Medgiz; 1963 (in Russian).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bykova A.F., Galan S.E., Malyagin V.Y., Subbotina S.N.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.